In addition, because docetaxel is often combined with ADT as an upfront treatment for routine management of metastatic prostate cancer, future studies to test the value of TCEAL1 in the context of combined chemo-hormonal therapy are necessary. The gene discussed is TCEAL1; the disease is metastatic prostate carcinoma.